血清PSA、ALP检测在前列腺癌骨转移诊断中的价值

目的 探讨血清PSA、ALP检测对前列腺癌（PCa）骨转移早期诊断的价值.方法 以全身核素骨显像为金标准,回顾性分析123例PCa（其中58例发生骨转移和65例未发生骨转移）患者血清PSA、ALP水平与骨转移的关系.结果 骨转移PCa组患者血清PSA、ALP水平均显著高于未发生骨转移PCa组（P〈0.05）.血清PSA≥20 μ g/L的PCa患者骨转移发生率（45.5%）明显高于PSA〈20μg/L的患者（1.63%）;血清ALP≥90 U/L的PCa患者骨转移发生率（39.02%）也明显高于ALP〈90 U/L的患者（8.13%）.结论 对于新诊断而未治疗的PCa患者,PSA≥20 μg/L和（或）ALP≥90 U/L时,应常规行全身核素骨显像检查,以早期诊断PCa骨转移.

The Application of Serum PSA ALP Measurement in Diagnosis of Bone Metastasis in Prostate Cancer Patients

Objective To evaluate the clinical value of serum prostate-specific antigen(PSA)and alkaline phosphatase(ALP) measurement in the diagnosis of prostate cancer patients with hone metastasis.Methods Serum PSA and ALP levels in 123 cases of prostate cancer patients, during which 58 ones have bone metastasis and the others do not have bone metastasis, was retrospectively analyzed to find the correlation between serum PSA ,ALP and bone metastasis. And use the bone scan as the diagnosis golden standard for bone metastasis. Results Both serum PSA and ALP levels in bone metastases patients were higher than the patients without bone metastases( P<0.05 ). The bone metastases incidence rate(45.5%) of the prostate cancer patients with a serum PSA ≥ 20 ug/L was higher than the incidence rate(1.63%) of the ones with serum PSA<20ug/L; the ones with a serum ALP ≥ 90 U/L which counted for 39.02% had a higher incidence rate of bone metastases than the ones with a serum ALP<90 U/L which counted for 8.13%.Conclusion For the definite prostate cancer patients without any treatment, to diagnose the bone metastasis early, nuclide bone scan is suggested as a routine detection, if the serum PSA ≥ 20 ug/L or the serum ALP ≥ 90 U/L.